He brings over 20 years of experience in business development, marketing, and portfolio strategy in the ophthalmic and pharmaceutical spaces.
Dr. Donnenfeld brings significant clinical leadership and innovation experience to expand company’s board of directors.
Library of ViewPoint drug candidates will accelerate development of novel alpha-crystallin chaperone compounds as a non-surgical treatment for age-related cataracts.
Plus, the company also announced the expansion of its Irvine co-headquarters.
The company’s lead investigational candidate is a treatment for presbyopia.
They'll support the company's efforts to expand its pipeline of potential ophthalmic therapies.
It entered into a licensing agreement with Cella Therapeutics.
The round was led by new investor LSP.
Ophthalmology industry veterans contribute 130+ years of combined experience to support presbyopia development program & pipeline expansion.
The company is developing a once-daily eye drop to correct for presbyopia.
It has appointed renowned ophthalmologists.
Get the most important news and business ideas for eyecare professionals every weekday from INVISION.
Advertisement